Company to Use Proceeds from Sale Combined with Strong Operating Cash Flow to Invest in Growth of Core Pharmaceutical Business NEW YORK, Dec. 20 /PRNewswire-FirstCall/ -- Pfizer Inc said today that it has completed the sale of its Pfizer Consumer Healthcare business to Johnson & Johnson for $16.6 billion or about $13.5 billion in after-tax proceeds. "The proceeds from this sale, combined with our strong operating cash flow, give us the flexibility to invest in the growth of our core pharmaceutical business while enhancing total return to shareholders through dividends and share purchases," said Jeffrey B. Kindler, Pfizer chairman and CEO. "We are committed to pursuing new products and technologies that complement our internal development programs and represent attractive, strategic opportunities to grow and to meet unmet medical needs," said David Shedlarz, Pfizer vice chairman. "We thank the colleagues of Pfizer Consumer Healthcare for their many contributions to Pfizer over the years," said Kindler. "We appreciate their commitment and dedication, especially as we reviewed strategic options for this business, culminating in today's closing. We wish them continued success in the future." DATASOURCE: Pfizer Inc CONTACT: Paul Fitzhenry, +1-212-733-4637, for Pfizer Inc Web site: http://www.pfizer.com/ Company News On-Call: http://www.prnewswire.com/comp/688250.html Company News On-Call: Pfizer's press releases are available through PR Newswire's Company News On-Call service on PRN's Web Site. Visit http://www.prnewswire.com/comp/688250.html

Copyright